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A B S T R A C T
Purpose: To test the new ILAE deﬁnition of drug-resistant epilepsy in a cohort study.
Methods: All children younger than 14 with two or more unprovoked seizures observed at our hospital
between 1994 and 2008 were included.
Results: Five hundred and eight patients were followed for an average of 90 months (range 24–168). The
probabilities of achieving seizure freedom, according to the ILAE criteria, with the ﬁrst, second, third and
fourth and subsequent therapeutic regimens were 65%, 29%, 27% and 21%, respectively. In the cohort, 87
patients met the criteria for drug-resistant epilepsy, which represents 19% of the treated patients
(n = 459) and 17% of the overall sample. The probability of meeting the criteria for drug-resistant
epilepsy was 11%, 11% and 13% at 2, 6 and 10 years respectively. Sixty two percent of drug resistant cases
were younger than 4 years old, 73% had an associated developmental delay and/or motor deﬁcit, 42% had
an identiﬁable structural cause of epilepsy and 32% had a speciﬁc epileptic syndrome. For drug-resistant
patients who tried additional therapeutic regimens, the probability of achieving a seizure-free state
without further recurrences was 23% and 27% at three and ﬁve years, respectively.
Conclusions: Compared with more stringent criteria, the new ILAE criteria classify a greater number of
patients with drug-resistant epilepsy. A signiﬁcantly higher proportion of cases meeting this deﬁnition
subsequently enter remission. A deﬁnition of drug-resistance that includes the additional criteria of
failure of a third antiepileptic drug or high seizure frequency may better identify patients with truly
drug-resistant epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
To date, the lack of a broadly accepted deﬁnition of drug-
resistant, refractory or intractable epilepsy has made it difﬁcult to
compare different studies about the subject. Recently, the
International League Against Epilepsy (ILAE) appointed a task
force under the Commission on Therapeutic Strategies to formu-
late a proposal for a consensus deﬁnition of drug-resistant
epilepsy. The report has recently been published.1 We considered
it important to test this new deﬁnition in an epidemiological study
aiming to investigate the following aspects of childhood epilepsy:
response to antiepileptic treatment, risk of developing drug-
resistant epilepsy, clinical features of drug-resistant epilepsy and
temporal evolution of drug resistant epilepsy.* Corresponding author at: Unidad de Neurologı´a Pedia´trica, Servicio de
Pediatrı´a, Hospital Torreca´rdenas, Paraje de Torreca´rdenas s/n, Almerı´a, Spain.
Tel.: +34 950 21 21 00; fax: +34 950016856.
E-mail addresses: jramoslizana@telefonica.net (J. Ramos-Lizana),
mrlucenilla83@hotmail.com (M.I. Rodriguez-Lucenilla), paguileralopez@gmail.com
(P. Aguilera-Lo´pez), javieraguirrerodriguez@orange.es (J. Aguirre-Rodrı´guez),
elicassinello@hotmail.com (E. Cassinello-Garcı´a).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2012.01.0092. Methods
2.1. Deﬁnitions and classiﬁcation criteria
Seizures were considered unprovoked when they occurred
without any known proximal precipitant. Epilepsy was deﬁned
as the occurrence of two or more unprovoked seizures at least 24 h
apart. Epilepsies were classiﬁed according to their aetiology as
idiopathic, cryptogenic or remote symptomatic, following the ILAE
criteria. In particular, epilepsies were classiﬁed as remote
symptomatic when they occurred in a patient with a history of
a neurological deﬁcit of pre- or perinatal origin or a prior
neurological injury such as central nervous system infection,
stroke or signiﬁcant head trauma.2 Therefore, this group included
patients with global developmental delay/mental retardation and
cerebral palsy. Classiﬁcation of patients by epileptic syndrome was
performed according to the revised 1989 ILAE classiﬁcation with
some modiﬁcations to include newly described syndromes.3 A
family history of unprovoked seizures was deﬁned as seizures
affecting a ﬁrst-degree relative (parent or sibling). Global
developmental delay was deﬁned as a developmental quotient
below 70% and mental retardation as an intelligence quotientvier Ltd. All rights reserved.
Table 1
Classiﬁcation of treatment outcome for a given therapeutic regimen.
Did seizures recur after
starting the therapeutic regimen?
Had a new therapeutic
regimen been initiated?
Had the required time interval to
consider the patient seizure freea elapsed?
Classiﬁcation of treatment
outcome
Yes No Yes Seizure freedom
No No Yes Seizure freedom
Yes Yes – Treatment failure
Yes No No Treatment failure
No No No Undetermined
a 12 months or 3 times the longest interseizure interval (determined from seizures occurring within the past 12 months) prior to starting a new therapeutic regimen,
whichever was longer.
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intelligence tests scores were not available. Motor deﬁcit was
considered present if there was hemiplegia, diplegia, quadriplegia
or ataxia in the context of cerebral palsy or as a result of a central
nervous system injury (e.g. infection, stroke or head trauma) that
occurred later in life.
Therapeutic regimen or schedule was considered to be any
combination of antiepileptic drugs (AEDs) in mono- or poly-
therapy. A change in dosage was not considered a change in
therapeutic regimen. To considered, a therapeutic regimen had to
be appropriate (safe and effective) and adequately applied (taken
at least in standard maintenance doses for a sufﬁcient amount of
time). Drugs considered inappropriate for the seizure type of the
patient (e.g. ethosuximide for partial seizures) or withdrawn due
to intolerable side effects were ignored for further analyses.
Compliance was assessed by directly questioning the child’s
parents. If compliance was in doubt, it was veriﬁed by means of
determining anti-epileptic drugs levels.
Categorisation of treatment outcome and classiﬁcation of drug
responsiveness of epilepsy were performed following ILAE
recommendations.1 Minor modiﬁcations and speciﬁcations were
introduced to adapt deﬁnitions to our study.
Treatment outcome was classiﬁed in three categories: (1)
‘‘seizure freedom’’: the patient was free of all types of seizures
for the last 12 months or three times the longest interseizure
interval (determined from seizures occurring within the past 12
months) prior to starting a new therapeutic regimen, whichever
was longer; (2) ‘‘treatment failure’’: unable to achieve a ‘‘seizure-
free’’ state on a given therapeutic regimen i.e., when a new
therapeutic regimen had been initiated or when seizures recurred
after starting a therapeutic regimen and the required time interval
to consider the patient seizure-free had not elapsed; (3)
‘‘undetermined’’: no recurrences had occurred after starting a
new therapeutic regimen but the required seizure-free interval
had not elapsed (see Table 1).
In evaluating the efﬁcacy of a therapeutic regimen, seizures
related to attempted medication withdrawal were not taken into
account. These were deﬁned as recurrences that occurred after
medication withdrawal but were not repeated after reinitiating the
drug.
Drug responsiveness of epilepsy was classiﬁed in three classes:
(1) ‘‘drug-resistant epilepsy’’: failure of adequate trials of two
tolerated and appropriately chosen and used AED schedules
(whether as monotherapy or in combination) to achieve seizure
freedom; (2) ‘‘drug-responsive epilepsy’’: achievement of seizure
freedom on the ﬁrst or second AED regimen; (3) ‘‘undeﬁned’’:
failure of only one therapeutic schedule or ‘‘treatment outcome’’
of the second therapeutic regimen classiﬁed as undetermined.
When a patient was ‘‘seizure free’’ and experienced one
recurrence, the ‘‘outcome’’ of the individual drug was classiﬁed
as ‘‘undetermined’’ and ‘‘drug responsiveness’’ as ‘‘undeﬁned’’. If
two seizures occurred, outcome to the individual drug was
categorised as ‘‘treatment failure’’ and drug responsivenessremained ‘‘undeﬁned’’. Epilepsy was redeﬁned as ‘‘drug resistant’’
if an additional AED failed.
2.2. Cohort selection
Torreca´rdenas Hospital is the reference hospital of Almerı´a
province in Spain and has the only electroencephalogram (EEG)
laboratory and paediatric neurology division in the province.
Between June 1st, 1994 and May 1st, 2008 all patients younger
than 14 years of age consecutively observed at our hospital for two
or more newly diagnosed unprovoked seizures at least 24 h apart
were enrolled in a prospective study. Patients with seizures limited
to the neonatal period, patients with seizures due to inborn errors
of metabolism or neurodegenerative disorders and children
already on antiepileptic treatment or who had been previously
examined in other centres were excluded. Consequently, all
patients were directly referred by primary care paediatricians or
were ﬁrst observed in our emergency department.
The study was approved by the ethical committee of
Torreca´rdenas Hospital and we obtained informed consent to
participate for each patient.
2.3. Initial evaluation
A standard EEG was performed for each patient upon epilepsy
diagnosis. If the standard EEG was normal, a sleep recording was
performed. Computed tomography (CT) or magnetic resonance
imaging (MRI) was performed at least in those cases with abnormal
neurological examination ﬁndings, focal seizures, focal EEG
abnormalities (except in the case of benign childhood epilepsy
with centro-temporal spikes) or West syndrome. Because this is an
observational study, the treating physician chose the AED to be
used. Some patients were not treated with AEDs.
2.4. Follow-up
All patients were followed by personal interviews for at least at
six to twelve months intervals until May 1st, 2010 (to allow for a
minimum of a two-year follow-up) or until a three-year remission
without an AED (i.e., three years with neither treatment nor
relapses). The number and dates of recurrences were recorded at
every visit.
Patients in remission were thereafter contacted by telephone
until they achieved ﬁve years without anti-epileptic treatment.
After that, patients were instructed to contact us if a relapse
occurred. Otherwise, patients were considered to be in remission.
We adopted this method to simplify the follow-up process because
previous studies showed that recurrence risk beyond ﬁve years
after medication withdrawal is very low.4 Patients were followed
for a maximum of 14 years.
In most instances of persistent seizures, AEDs were pushed to
the maximum tolerated doses before a trial with a new therapeutic
regimen was considered. In cases when treatment failed due to
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therapy was offered. In general, medication withdrawal was
attempted after a two-year seizure-free period.
Classiﬁcation of treatment outcome and drug responsiveness of
epilepsy was done retrospectively with prospectively obtained
data regarding seizure recurrence and remission.
2.5. Analysis
The probability of developing drug-resistant epilepsy was
calculated using Kaplan–Meier curves and percentages at two, six
and ten years after diagnosis. All treatments initiated before May
1st, 2010 were taken into account for these analyses. Responses to
different treatment schedules were calculated as percentages. For
this latter analysis only treatments initiated before May 1st, 2008
were considered, to allow for a minimum of two years of follow-up.
Calculations were performed by means of SPSS statistical software
for Windows, version 15.0.
3. Results
3.1. General features of the sample
Five hundred and twenty patients were enrolled in the study.
Nine children were lost to follow-up before completing a minimum
follow-up of two years, and three patients died within two years of
diagnosis. Consequently, 508 patients were followed for more than
two years and constituted the study sample. Thereafter, another 26
patients were lost and six died. Twelve of the 26 (46%) lost cases
were seizure free and without antiepileptic treatment for more
than three years. Overall, we lost contact with only 6.7% (9 + 26)
cases in the original sample.
Patients were followed for a mean of 90 months (SD 45, range
24–168). Out of the 508 patients, 390 (77%) were followed for more
than four years, 301 (59%) for more than six years, 210 (41%) for
more than eight years, 131 (26%) for more than ten years and 75
(15%) for more than 12 years.
The mean age at diagnosis was 4.9 years (SD 3.8). Ninety-four
(18%) of the children were younger than one year old when they
were diagnosed with epilepsy, 375 (74%) were between one and
ten years of age and 39 (8%) were 11 years old or older. A total of
271 were male and 237 were female. Neuroimaging was
performed in 438 (86%) patients: CT in 119, MRI in 207 and both
in 112. Aetiology was remote symptomatic in 164 cases (32%),
cryptogenic in 140 (28%) and idiopathic in 204 (40%).
3.2. Course and effectiveness of the ﬁrst treatment
Forty-nine (9.6%) patients were not treated, and 459 received a
ﬁrst therapeutic regimen. The ﬁrst AED, used in monotherapy, wasTable 2
Categorisation of treatment outcome. Classiﬁcation was made with data at the end of
without further recurrences. % represents the number of patients classiﬁed in each cat
1st schedule
n = 459
2nd sch
n = 128
‘‘Seizure freedom’’ n (%) [95% CI] 299 (65%)
[62,69]
37 (29%
[21,35]
‘‘Treatment failure’’ n (%) [95% CI]
With treatment change 138 (30%)
[26,34]
82 (64%
[56,72]
Without treatment change 20 (4%)
[2,6]
8 (6%)
[2,10]
Total 158 (34%)
[30,38]
90 (70%
[62,78]
‘‘Undetermined’’ n (%) [95% CI] 2 (0.4%)
[0.1,2]
1 (0.8%)
[0.1,4]valproic acid in 291, carbamazepine in 66, oxcarbazepine in 49,
phenobarbital in 17, lamotrigine in ﬁve, vigabatrin in ﬁve,
phenytoin in four, ethosuximide in three, clonazepam in two
and levetiracetam in one. In 16 patients diagnosed with West
syndrome, the ﬁrst regimen consisted of oral corticoids or ACTH
plus valproic acid.
The mean of the longest interseizure interval prior to starting
treatment was 72 days (SD 130). It was fewer than 122 days (four
months) in 371 (81%) [95% CI: 77,85] of the patients and fewer than
244 days (eight months) in 418 (91%) [95% CI: 88,94]. Conse-
quently, the time interval required to consider a patient seizure
free was 1 year in 81% [95% CI: 77,85] of the cases and 2 years in
91% [95% CI: 88,94].
One hundred and eighty-eight patients (41% of the treated
patients) [95% CI: 36,46] did not have recurrences after initiating
antiepileptic treatment. Two hundred and seventy-one had one or
more recurrences; 160 out of these 271 patients were switched to
another therapeutic regimen, but 111 (41%) [95% CI: 35,47]
eventually achieve seizure freedom with the ﬁrst schedule.
Consequently, 299 out of 459 treated patients (65%) became
seizure free with the ﬁrst AED.
3.3. Categorisation of treatment outcome
Four hundred and ﬁfty-nine patients were treated. Twenty-nine
out of a total of 690 AEDs tested in mono- or polytherapy (4%) [95%
CI: 2,6] were withdrawn due to unacceptable side effects and were
not considered for further analysis. Table 2 shows the categorisa-
tion of treatment outcome.
3.4. Classiﬁcation of drug responsiveness of epilepsy
A total of 88 (19%) [95% CI: 15,23] treated patients (n = 459) met
criteria for drug- resistant epilepsy at some point during their
follow-up, 348 (76%) [95% CI: 72,80] were classiﬁed as drug
responsive and 23 (5%) [95% CI: 3,7] as undeﬁned.
For the overall sample, i.e., including untreated patients
(n = 508), the proportion of drug-resistant epilepsy was 17%
[95% CI: 14,21]. The cumulative probability of developing drug-
resistant epilepsy calculated by Kaplan–Meier curves was 10%
[95% CI: 7,13], 19% [95% CI: 15,23] and 23% [95% CI: 19,27] at two,
six and ten years after diagnosis, respectively. Table 3 shows the
classiﬁcation of drug responsiveness of epilepsy at two, six and
ten years after diagnosis. Proportions in the table indicate
probabilities of meeting criteria at each time point (not cumula-
tive probabilities).
At ﬁrst glance, it may seem inadequate to calculate the
percentage of drug-resistant patients out of the total sample
(including untreated patients). However, from an epidemiological
point of view, to study the incidence of drug-resistant epilepsy in the study period. Consequently, ‘‘seizure freedom’’ refers to a seizure-free period
egory/total number of patients treated with this schedule.
edule 3rd schedule
n = 74
4th and subsequent schedules
n = 47
) 20 (27%)
[17,37]
10 (21%)
[9,33]
) 53 (72%)
[62,82]
36 (77%)
[65,89]
1 (1%)
[0.1,7]
1 (2%)
[0.3,11]
) 54 (73%)
[63,83]
37 (79%)
[67,91]
0 0
Table 3
Classiﬁcation of drug responsiveness at 2, 6 and 10 years after an epilepsy diagnosis. Only patients with sufﬁcient follow-up at each time interval were considered.
At 2 years At 6 years At 10 years
Treated (n) 459 292 137
Untreated (n) 49 31 14
Total sample (n) 508 323 151
Drug-resistant epilepsy (n) 58 (35 + 23)a 36 (26 + 10)a 19 (18 + 1)a
% of total sample [95% CI] 11% [9,14] 11% [8,14] 13% [7,18]
% of treated patients [95% CI] 13% [10,15] 12% [9,16] 14% [8,19]
Drug-responsive epilepsy (n) 304 235 114
% of treated patients [95% CI] 66% [62,70] 81% [77,85] 83% [77,89]
Undeﬁned (n) 97 (25 + 72)b 21 (2 + 19)b 4 (0 + 4)b
% of treated patients [95% CI] 21% [17,25] 7% [4,10] 3% [0,6]
a Total number (with switch to a third AED + without change to a third AED).
b Total number (two therapeutic schedules but insufﬁcient time + only one therapeutic regimen).
Table 4
Speciﬁc aetiologies of drug resistant epilepsies (n = 88) with ﬁndings in neuroimaging studies.
Aetiology n % Neuroimaging ﬁndings n %
Neurocutaneous disordersa 4 4 Typical ﬁndings 4 4
Brain malformationsb 14 16 Speciﬁc ﬁndings 14 16
Chromosomal abnormalities 3 3 Ventricular enlargement plus cortical atrophy 1 1
Normal 2 2
Pre or perinatal hypoxic–ischaemic lesionsc 9 10 Focal or diffuse multicystic encephalomalacia 5 6
Periventricular leukomalacia 2 2
Parasagittal necrosis 1 1
Normal 1 1
Postnatal acquired lesionsd 6 7 Destructive lesions 6 7
Nonspeciﬁc global developmental delay/mental retardatione 16 18 Normal 16 18
Othersf 1 1 White matter alteration 2 2
Idiopathic 15 17 Normal 15 17
Cryptogenic 20 23 Normal 20 23
a Tuberous sclerosis: 3, Sturge–Weber syndrome: 1.
b Hemimegalencephaly: 1, corpus callosum agenesis: 2, periventricular heterotopia: 1, polymicrogyria: 1, lissencephaly: 2, hydrocephalus: 2, focal cortical displasia: 1,
hydranencephaly: 1, pachygyria: 1, arachnoid cyst: 1.
c Prematurity: 6, neonatal hypoxic–ischaemic encephalopathy 3.
d CNS tumours: 2, head trauma: 2, encephalitis: 1, stroke; 1.
e Normal MRI, no motor disability and no deﬁnite cause.
f Congenital muscular dystrophy.
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proportion of drug-resistant patients, not only out of the total
number of treated patients but also out of the total number of
epileptic patients.
Eighty-one (18%) out of 459 treated patients experienced a
recurrence after a seizure-free period. In this setting, to consider
a patient drug resistant according to ILAE recommendations,
the current AED and a second AED must have failed, ignoring
any other AED previously utilised (see Section 2). With the
objective of investigating the consequences of this recommen-
dation, we recalculated the number of drug-resistant patients,
this time taking into account all AED employed in a patient.
As a result, 97 children met the criteria for drug-resistant
epilepsy, the percentage of drug-resistant epilepsy calculated
amongst treated patients rose to 21% [95% CI: 17,25], and
the percentage amongst the total sample rose to 19% [95% CI:
16,22].
3.5. Clinical features of drug-resistant patients
See Tables 4 and 5.
3.6. Temporal evolution of drug resistant epilepsy
Eighty-eight patients fulﬁlled the criteria of drug-resistant
epilepsy. Forty-seven (53%) did so within 24 months, 58 (66%)
within 36 months and 67 (76%) within 48 months of diagnosis.Nineteen (22%) patients had a ‘‘seizure-free period’’ before meeting
the criteria for drug-resistant epilepsy.
To calculate the probability of becoming seizure-free after
having met the criteria for drug resistance, we only considered
patients in whom three or more regimens were initiated. The main
reason for not having attempted more regimens was that the
current AED had not been considered a failure at the end of the
study period. Sixty-seven out of 88 children with drug-resistant
epilepsy tried three or more AED regimens: 37 (55%) [95% CI:
43,67] cases achieved a seizure-free period (deﬁned according to
ILAE criteria). 25 cases (37%) [95% CI: 25,49] achieved a seizure-
free period without further recurrences. Note that these ﬁgures do
not necessarily coincide with those in Table 2 for various reasons.
First, the table shows responses to each schedule, and we are now
dealing with the response to third or subsequent schedules. Second,
only those treatments initiated before May 1st, 2008 are
considered in Table 2 (see Section 2.5). Third, patients with two
failed drugs may not fulﬁl drug-resistant epilepsy criteria if they
experienced a seizure-free period (see Section 2).
Twenty-two of the 67 cases (33%) [95% CI: 22,44] had been
seizure-free for more than two years at last contact, 14 (21%) [95%
CI: 11,31] for more than four years, nine (13%) [95% CI: 5,21] for
more than six years and seven (10%) [95% CI: 3,17] for more than
eight years. A total of 15 patients (22%) [95% CI: 12,32] were not
taking antiepileptic treatment.
The Kaplan–Meier estimate of the probability of attaining a
seizure-free period without further recurrences until the end of the
Table 5
Clinical features of drug-resistant epilepsies (n = 88).
n %
Male sex 52 59
Age at diagnosis, mean 3.27 (3.5 SD)
<1 year 29 33
1–3 years 26 29
4–13 years 33 37
Associated handicaps
Global developmental delay/mental retardation 49 56
Motor deﬁcit 15 17
Both 14 16
Prior febrile seizures 6 7
Prior neonatal convulsions 9 10
Family history of unprovoked seizures 5 6
Abnormal neuroimaging 53 60
Frequency of seizures in the year before fulﬁlling criteria of drug resistance
Daily 29 33
1/week but <1/day 18 20
1/month but <1/week 18 20
4–11/year 15 17
2–3/year 4 4
1/year 4 4
Syndromic diagnosis
Speciﬁc 28 32
Benign childhood epilepsy with centrotemporal spikes 4 4
Early onset benign childhood occipital epilepsy
(Panayiotopoulos type)
1 1
Myoclonic epilepsy in infancy 1 1
Epilepsy with myoclonic–atonic seizures 4 4
Childhood absence epilepsy 4 4
Juvenile myoclonic epilepsy 1 1
West syndromea 9 10
Lennox–Gastaut syndrome 1 1
Dravet syndrome 3 3
Nonspeciﬁc 60 68
Remote symptomatic partial epilepsy 31 35
Cryptogenic partial epilepsy 13 15
Remote symptomatic generalised epilepsy 8 9
Cryptogenic generalised epilepsy 2 2
Remote symptomatic epilepsy with focal and
generalised seizures
5 6
Cryptogenic epilepsy with focal and generalised
seizures
1 1
a Six with evolution to remote symptomatic partial epilepsy and 1 to cryptogenic
partial epilepsy.
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29% [95% CI: 17,41] and 37% [95% CI: 25,49] at 1, 2, 3, 4 and 5 years,
respectively. Seizure-freedom is deﬁned according to ILAE criteria.
4. Discussion
Although this is a hospital-based study, it was designed to
obtain a representative sample of the general population.
Additional details about the sample selection process and the
clinical features of the ﬁrst 343 patients of the cohort have
previously been published.5,6
Another limitation of this study is that classiﬁcation of
treatment outcome and drug responsiveness of epilepsy was
performed retrospectively. However, we do not think that this is a
major problem because the prospective follow-up of the cohort
was designed for a previous study with similar characteristics,5,6
and the criteria applied are not affected by subjective interpreta-
tions.
The lack of a broadly accepted deﬁnition of drug-resistant,
refractory or intractable epilepsy has made it difﬁcult to compare
studies on this matter. For this reason, the consensus deﬁnition
proposed by the ILAE1 is welcomed. To our knowledge this is the
ﬁrst time that these criteria were employed in a ﬁeld study;
therefore, it is not surprising that we have encountered some
practical problems applying it.The ﬁrst problem was the variable time interval required to
consider a patient seizure-free; this interval may change over time
even in the same patient. However, our study shows that it is one
year for 81% of the cases and 2 years for 91%. Utilisation of a
variable time interval may be more precise, but it signiﬁcantly
increases the computation time and is a potential source of errors.
It may be more practical to employ a ﬁxed time interval when
dealing with a large number of patients in the context of an
epidemiological study.
The second question had to do with when to consider an AED as
failed. To test the effectiveness of an AED, the ILAE proposal only
requires that it have been used in a clinically effective dose for
‘‘enough time’’, without further explaining what ‘‘enough time’’
means. However, it is common practice to push the AED to the
maximum tolerated or recommended doses before considering it
as failed. Our study shows that this practice results in 41% of
patients becoming seizure-free. As this process may take months, it
is not possible to know if the observed outcome is the effect of the
higher dose and/or a consequence of the natural disease course. In
any case, a signiﬁcant proportion of patients treated with a given
AED had a number of seizures, sometimes over a long time interval,
whilst taking a speciﬁc treatment. In these cases it was difﬁcult to
choose between the maximum interseizure interval before
initiating treatment or after initiating treatment as the basis to
decide whether a patient was seizure free. It was also difﬁcult to
decide when a therapeutic regimen had failed. To make things
easier, we chose to maintain the maximum interseizure pre-
treatment interval, and for epidemiological purposes, we classiﬁed
a therapeutic regimen as treatment failure when a new regimen
had been initiated or when seizures recurred once or more after
starting a therapeutic regimen and at a given time interval (e.g.,
two years) the required time period to consider the patient
seizure-free had not elapsed.
A third question is related to the fact that the classiﬁcation
scheme does not specify how recurrences related to attempted
medication withdrawal should be managed. In accordance with
the spirit of the proposal, we chose to ignore them because
presumably, they are due to lack of AED efﬁcacy.
Regarding the probability of response to the ﬁrst and
subsequent therapeutic schedules, we found that the probability
of attaining seizure freedom was 65% with the ﬁrst regimen. This
ﬁgure is quite similar to the ﬁndings of a large, pragmatic,
randomised controlled trial.7,8 The probability of achieving seizure
freedom was 29% with the second, 27% with the third and 21% with
the fourth and subsequent schedules (number of patients attaining
seizure freedom with a treatment schedule/number of patients
treated with this schedule). These last outcomes are considerably
better than those in a previous study of adolescent and adults9,10
and slightly better than those observed in a previous study of the
ﬁrst 343 patients of our cohort.6 These results show that patients
with drug-resistant epilepsy according to the ILAE criteria still
have a signiﬁcant likelihood of entering in remission with
subsequent treatment schedules (see below).
The reported incidence of drug-resistant epilepsy in children
ranges between 6% and 24%.6,11–14 As expected, the incidence
depends on the diagnostic criteria employed, which differ
signiﬁcantly between studies. Some used stringent criteria, which
require a high frequency of seizures during a given length of time,
and others used broader criteria that do not require a high seizure
frequency. In two studies, refractoriness was deﬁned as failure of
more than two AEDs with an average of more than one seizure per
month for 18 months and no more than three consecutive
seizure-free months during this interval. In these studies, 9%6 and
10%13 of patients met the criteria for refractory epilepsy. Three
other studies employing similar criteria reported ﬁgures of 6%,12
8%11 and 14%.14 The variability in these studies does not appear to
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different sample features and follow-up time.6 On the other hand,
the rate of drug-resistant epilepsy substantially increases when
broader criteria are employed. One study deﬁned refractoriness as
‘‘no ﬁve-year remission ever during a follow-up of at least ten
years’’ and found a 19% rate of refractory epilepsy.15 In a second
study, the criterion was ‘‘failure of two AEDs’’, and the rate was
23%.14 A third study used the criterion ‘‘failure to reach a one-year
terminal remission’’, and the ﬁgure was 24%.6 In short, the
incidence of drug-resistant epilepsy in children ranges from 6 to
14% in studies that use stringent criteria and from 19 to 24% in
studies that employ broader criteria.
Some patients experienced a recurrence after a seizure-free
period. In this setting, to consider a patient drug-resistant
according to ILAE recommendations, the current AED and a second
AED must have failed, ignoring any other AED previously utilised
(see Section 2). This approach slightly reduces the incidence of
drug-resistant epilepsy from 19% to 17%.
Regarding clinical characteristics of drug-resistant patients, we
observed predominance in younger children (62% younger than
four years old) and a high prevalence of associated handicaps
(global development delay/mental retardation and/or motor
deﬁcit in 73%). With respect to aetiology, 40% of the cases had a
normal neurological examination and no identiﬁable structural
lesions on neuroimaging, 18% had no identiﬁable structural cause
for epilepsy but had nonspeciﬁc global developmental delay/
mental retardation before epilepsy onset, and 42% had a deﬁnite
cause of epilepsy. Although the causes were heterogeneous, the
most frequent were cerebral malformations (16% of the drug-
resistant epilepsies) and pre- or perinatal hypoxic-ischaemic
lesions (10%). It was possible to diagnose a speciﬁc epileptic
syndrome in only 32% of the cases. Syndromes that usually have a
good outcome, such us benign childhood epilepsy with centro-
temporal spikes, Panayiotopoulos syndrome, myoclonic epilepsy
in infancy, childhood absence epilepsy and juvenile myoclonic
epilepsy, were diagnosed in 12% of the cases, and syndromes with a
known poor prognosis, including West syndrome, Lennox syn-
drome, Dravet syndrome and epilepsy with myoclonic–atonic
seizures, accounted for another 20%. The rest were ill-deﬁned cases
with predominance of epilepsies with focal seizures and remote
symptomatic aetiology (35%). A previous study that deﬁned
refractory epilepsy as the failure of two AEDs found similar
results.14
Another important clinical aspect is seizure frequency: 73% of
our cases had one or more seizures per month, but 8% only had one
to three per year. It is evident that the second group of cases does
not pose the same therapeutic problems as those with very
frequent seizures.
Drug responsiveness is a dynamic process; some patients may
attain seizure freedom and then become drug resistant, whilst
others may enter remission after having fulﬁlled the criteria for
drug resistance. In the present study, 22% of drug-resistant patients
had a previous seizure-free period. On the other hand, 51% later
attained a seizure-free period and 37% entered a seizure-free
period without further recurrences. At the end of the study, 19% of
our drug-resistant cases were seizure free for more than four years,
and 20% were without antiepileptic treatment. A recent study in
children that also deﬁned drug resistance as failure of two AEDs
found similar results.16 Nevertheless, remission was attained
earlier in our study: we found a probability of achieving a period of
seizure freedom (one year in most of the cases) without further
recurrences of 23%, 29% and 37% at three, four and ﬁve years,
respectively, whereas the other study had proportions of patients
entering and remaining in one-year remission of 19%, 40% and 47%
at ﬁve, ten and 12 years, respectively. In any case, it must be
emphasised that a signiﬁcant proportion of drug-resistant epilep-sies deﬁned as the failure of two AEDs may later enter remission.
This is an important point when surgical treatment is under
consideration. However, this proportion is considerably lower
when failure of three antiepileptic regimens or failure of two
antiepileptic regimens plus a high frequency of seizures for a given
length of time are required for a deﬁnition of drug-resistance. We
previously found that after failure of three antiepileptic regimens,
only 15% of patients were seizure free for more than one year at last
contact. In this study, drug-resistant epilepsy was deﬁned as
failure of 2 AEDs plus an average of more than one seizure per
month for 18 months and no more than three consecutive
seizure-free months during this interval.6 In patients fulﬁlling
these criteria, only 7% later had a remission of at least two years. In
another study employing the same criteria, only 20% of patients
experienced a remission of at least one year, and 13% were in
remission for at least one year at last contact.14
Some patients become drug resistant after a variable time
interval, so the cumulative probability of developing drug-
resistant epilepsy increases with time. In our sample, this
probability was 10%, 19% and 23% at two, six and ten years,
respectively. Conversely, there are patients who enter remission
after having fulﬁlled drug-resistance criteria. Consequently, the
probability of meeting criteria for drug resistance at a time point
remains relatively constant over time: 11%, 11% and 13% at two, six
and ten years from diagnosis, respectively. This is an important
aspect to consider when interpreting incidence and prevalence
studies.
In conclusion, the present ILAE’s deﬁnition of drug-resistant
epilepsy is a broad criteria deﬁnition. Compared with deﬁnitions
with more stringent criteria, it yields a higher incidence of drug-
resistant epilepsy and includes patients with less frequent
seizures. A signiﬁcant proportion of the cases meeting the ILAE
criteria eventually enter remission. Additional criteria requiring
high seizure frequency for a given length of time or failure of three
antiepileptic regimens may better identify patients with truly
drug-resistant epilepsy. Perhaps the broader deﬁnition may be
more suitable for selecting patients for thorough evaluations, and
the most restrictive one may be more appropriate for therapeutic
considerations.
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